---
title: "里昂：升康龙化成目标价至 28.8 港元 维持 “跑赢大市” 评级"
description: "里昂发布研报称，康龙化成 (03759，将 2025 年营收增长指引由同比增 10% 至 15%，上调至 12 至 16%，并预期经调整非国际财务报告准则净利润将实现双位数增长。该行认为对今年末季至明年而言，康龙化成上调指引及积存订单增加属可喜。里昂上调康龙化成 2025 至 2027 年营收与净利预测，H 股目标价由 24.7 港元升至 28.8 港元，A 股目标价由 34.8 元人民币升至 4"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263667131.md"
published_at: "2025-10-31T06:12:04.000Z"
---

# 里昂：升康龙化成目标价至 28.8 港元 维持 “跑赢大市” 评级

> 里昂发布研报称，康龙化成 (03759，将 2025 年营收增长指引由同比增 10% 至 15%，上调至 12 至 16%，并预期经调整非国际财务报告准则净利润将实现双位数增长。该行认为对今年末季至明年而言，康龙化成上调指引及积存订单增加属可喜。里昂上调康龙化成 2025 至 2027 年营收与净利预测，H 股目标价由 24.7 港元升至 28.8 港元，A 股目标价由 34.8 元人民币升至 40.6 元人民币，均维持 “跑赢大市” 评级。

智通财经 APP 获悉，里昂发布研报称，康龙化成 (03759,300759.SZ) 将 2025 年营收增长指引由同比增 10% 至 15%，上调至 12 至 16%，并预期经调整非国际财务报告准则净利润将实现双位数增长。该行认为对今年末季至明年而言，康龙化成上调指引及积存订单增加属可喜。里昂上调康龙化成 2025 至 2027 年营收与净利预测，H 股目标价由 24.7 港元升至 28.8 港元，A 股目标价由 34.8 元人民币升至 40.6 元人民币，均维持 “跑赢大市” 评级。

### Related Stocks

- [300759.CN - 康龙化成](https://longbridge.com/zh-CN/quote/300759.CN.md)
- [03759.HK - 康龙化成](https://longbridge.com/zh-CN/quote/03759.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pharmaron To Raise HK$1.3 Billion in Share Placement | Pharmaron Beijing Co Ltd :SAYS IT PLANS TO PLACE 58.4 MILLION NEW H-SHARES AT HK$22.82 PER SHARESAYS IT EXPECTS TO RAISE | [Link](https://longbridge.com/zh-CN/news/272620883.md) |
| Pharmaron Beijing Announces Private Placement of 58 Million New H Shares | Pharmaron Beijing Co. Ltd. has announced a private placement of 58,440,762 new H shares under its general issuance manda | [Link](https://longbridge.com/zh-CN/news/272610619.md) |
| TAV Airports FY Net Profit Shrinks To 2.82 Bln Lira YOY, Proposes To Pay Dividend At Gross 3.61 Lira Per Share, Announces 2026 Guidance | TAV Airports reported a FY net profit of 2.82 billion lira, down from 6.56 billion lira year-over-year. The company's re | [Link](https://longbridge.com/zh-CN/news/276201362.md) |
| Pharmaron Acquires Majority Stake in Biortus for RMB1.3 Billion | Pharmaron Beijing Co., Ltd. has acquired an 82.54% stake in Biortus for approximately RMB1.3 billion, making Biortus a s | [Link](https://longbridge.com/zh-CN/news/263101055.md) |
| Pharmaron Raises HK$1.32 Billion via H-Share Placement to Fund Capacity Expansion | Pharmaron Beijing Co., Ltd. has raised approximately HK$1.32 billion through the placement of 58,440,762 new H shares at | [Link](https://longbridge.com/zh-CN/news/273351963.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。